Introduction {#Sec1}
============

The prevalence of osteoarthritis of the knee (OA) is increasing worldwide and this burden will continue to increase owing to aging of the general population \[[@CR95]\]. Consequent to an increase in incidence is the rise in the number of patients with knee OA who are prone to further deterioration of the knee. It therefore is important to better understand, control, and attempt to prevent further progression of disease in patients with knee OA.

In 2007, Belo et al. \[[@CR4]\] published the first systematic review on prognostic factors for progression of knee OA. They found that generalized OA and hyaluronic acid levels were associated with progression of knee OA. Knee pain, baseline radiographic severity, sex, quadriceps strength, knee injury, and regular sport activities were not associated. For the remaining factors the evidence was limited or conflicting. Their literature search had been performed up to December 2003; however, many articles studying radiographic progression of knee OA have been published in the decade since that review. Therefore, we performed an update of the systematic review of observational studies by Belo et al. \[[@CR4]\] to determine the currently available evidence on prognostic factors for radiographic progression of knee OA.

Search Strategy and Criteria {#Sec2}
============================

Literature Search {#Sec3}
-----------------

In the review by Belo et al. \[[@CR4]\], the search of the literature had been performed in MEDLINE and EMBASE for all available observational studies up to December 2003. We searched in MEDLINE and EMBASE from December 2003 up to February 2013. Key words were: knee, osteoarthritis (or arthritis, or arthrosis, or degenerative joint disease), progression (or prognosis, or precipitate, or predictive), and case-control (or cohort, or longitudinal, or follow-up). Articles were reviewed for inclusion independently by two authors (ANB and JNB or JR). The following inclusion criteria were used: 85% or more of participants in the analyses for OA progression had radiographic evidence of knee OA at baseline; the study investigated determinants associated with radiographic knee OA progression; radiographic progression was the outcome measure; the study had a case-control or cohort design with a minimal 1-year followup; full text of the article was available; the study was in English, Dutch, German, or French. Studies that observed the incidence of knee OA were excluded. A detailed description of our search strategy is available online (Appendix 1. Supplemental materials are available with the online version of CORR^®^). All articles were reviewed for inclusion independently by two authors (ANB and JNB or JR). Studies that used MRI features to define OA progression were excluded. However, studies determining MRI features as prognostic factors were included.

Methodologic Quality {#Sec4}
--------------------

The same methodologic quality assessment criteria as in the original review by Belo et al. \[[@CR4]\] were used for this review (Table [1](#Tab1){ref-type="table"}). These criteria were based on established criteria used in systematic reviews of prognostic factors for patients with musculoskeletal disorders and were described by Lievense et al. \[[@CR49]\], Scholten-Peeters et al. \[[@CR69]\], and Altman \[[@CR1]\]. The criteria cover the internal validity and the informativeness of the study. All included articles were scored independently by two authors (ANB and JNB or JR). Cohen's kappa coefficient (κ) was calculated to indicate the interrater agreement.Table 1Methodologic quality assessment criteriaStudy population Description of source population Valid inclusion criteria Sufficient description of inclusion criteriaFollowup Followup at least 1 year Prospective or retrospective data collection Loss to followup ≤ 20% Information about loss to followup (selective for age, sex, or severity)Exposure Exposure assessment blinded for the outcome Exposure measured identically in the studied population at baseline and followupOutcome Outcome assessment blinded for exposure Outcome measured identically in the studied population at baseline and followupAnalysis Measure of association or measures of variance given Adjusted for age, sex, and severityReprinted with permission of John Wiley and Sons from Belo JN, Berger MY, Reijman M, Koes BW, Bierma-Zeinstra SM. Prognostic factors of progression of osteoarthritis of the knee: a systematic review of observational studies. *Arthritis Rheum.* 2007;57:13--26.

Data Extraction {#Sec5}
---------------

Study population characteristics, observed risk factors, definitions of knee OA progression, and measures of association were extracted.

Evidence Synthesis {#Sec6}
------------------

Odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) were pooled when there was consistency in definition of study population, measured determinants, and assessed outcome (using Review Manager \[RevMan\], Version 5.3; Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). We tested for heterogeneity with the chi-square and I-square tests. If heterogeneity was absent, a fixed effects model was applied to calculate pooled OR through the Mantel Haenszel test. In the absence of consistency among definitions for OA, a best-evidence synthesis was used to summarize the data. The level of evidence was based on the updated guidelines by Furlan et al. \[[@CR34]\] and was divided into the following levels: (A) strong, ie, consistent (\> 75%) findings among two or more high-quality studies; (B) moderate, ie, findings in one high-quality study and consistent findings in two or more low-quality studies; (C) limited, ie, findings in one high-quality study or consistent findings in three or more low-quality studies; and (D) conflicting or inconclusive evidence, ie, less than 75% of the studies reported consistent findings, or the results were based on only one study. High quality was defined as a quality score of 9 or greater (\> 65% of the maximal attainable score). When performing the best-evidence synthesis, we only differentiated between high- and low-quality studies.

Studies Included {#Sec7}
----------------

Of the 1912 articles identified using our search strategy, 43 met the inclusion criteria \[[@CR2], [@CR5], [@CR7], [@CR11], [@CR13], [@CR19], [@CR20], [@CR25]--[@CR28], [@CR30], [@CR35], [@CR38]--[@CR44], [@CR46], [@CR48], [@CR50]--[@CR52], [@CR55], [@CR57]--[@CR62], [@CR64]--[@CR66], [@CR73], [@CR74], [@CR78], [@CR85], [@CR88], [@CR91]--[@CR93]\]. Belo et al. reviewed 36 articles \[[@CR3], [@CR8], [@CR12], [@CR14]--[@CR16], [@CR18], [@CR21]--[@CR24], [@CR29], [@CR31], [@CR32], [@CR37], [@CR45], [@CR47], [@CR53], [@CR54], [@CR56], [@CR63], [@CR70]--[@CR72], [@CR75]--[@CR77], [@CR79]--[@CR83], [@CR87], [@CR89], [@CR94], [@CR96]\]; therefore the total number of included studies was 79, studying 59 different determinants for the progression of knee OA (Table [2](#Tab2){ref-type="table"}). Three reviewers scored 559 items for the methodologic quality assessment of the 43 newly included articles and agreed on 519 items (93%; κ = 0.79). The 53 disagreements were resolved in a single consensus meeting. Seventy-two of the 79 included articles were scored as high quality (score, 9--13), and only one article had the maximum attainable score. The remaining seven were scored as low quality, however no article was scored less than 6. Six different criteria were used for the inclusion of participants with OA and 13 definitions were applied to define radiographic OA progression. Furthermore, there were differences in how the determinants under study were measured, ie, continuous, dichotomous, or categorical with varying cut-off points.Table 2Study characteristics of the reviewed manuscripts (n = 79)StudyNumber of participantsFollowup (months)Definition of OA for inclusionMean age in years ± SDWomen (%)Quality scoreSharma et al. \[[@CR78]\], 201095030K/L63.6 ± 7.86213Brouwer et al. \[[@CR13]\], 200716972K/L66.4 ± 6.75912Cerejo et al. \[[@CR16]\], 200223018K/L64 ± 10.87312Dieppe et al. \[[@CR21]\], 199741537.6\*K/L65.36812Felson et al. \[[@CR29]\], 200322315 and 30OARSI66.2 ± 9.44212Madan-Sharma et al. \[[@CR50]\], 200818624ACR criteria60.28112McAlindon et al. \[[@CR53]\], 1996556120K/L70.36312Sharma et al. \[[@CR79]\], 200123018K/L, JSW64.0 ± 11.17512Spector et al. \[[@CR81]\], 19945824K/L56.8 ± 5.910012Vilim et al. \[[@CR87]\], 20024836K/L, JSW62.8 (48--74)7112Bagge et al. \[[@CR3]\], 19927448K/LNR5711Benichou et al. \[[@CR5]\], 20106712OARSI60 ± 96411Botha-Scheepers et al. \[[@CR11]\], 20088624ACR criteria618011Brandt et al. \[[@CR12]\], 19998231.5\*K/L70.17011Denoble et al. \[[@CR20]\], 20116936K/L64.5 ± 10.17111Dieppe et al. \[[@CR23]\], 19936060cOA and rOA62.2 ± 1.56511Dieppe et al. \[[@CR22]\], 200034996K/L65.36811Ledingham et al. \[[@CR47]\], 199518824K/L71 (34--91)6311Miyazaki et al. \[[@CR56]\], 20027472K/L, JSW69.9 ± 7.88111Nevitt et al. \[[@CR59]\], 2010175430K/L63 ± 86311Niu et al. \[[@CR61]\], 2009262330K/L62.4 ± 8.05911Sharif et al. \[[@CR72]\], 19957560K/L64.2 ± 11.66911Sharif et al. \[[@CR75]\], 19955760JSWNRNR11Sharif et al. \[[@CR76]\], 20004060K/L65.2 ± 9.96111Sharif et al. \[[@CR74]\], 200411560K/L63.6 ± 9.75511Sharif et al. \[[@CR73]\], 200711560K/L63.6 ± 9.75511Zhang et al. \[[@CR96]\], 199855196K/L71 (63--91)10011Zhang et al. \[[@CR94]\], 200047396K/L71 (63--91)10011Bettica et al. \[[@CR8]\], 200221648Osteophytes, JSWNR10010Cooper et al. \[[@CR18]\], 200035461.2\*K/L71.37210Dam et al. \[[@CR19]\], 200913821ACR criteria604810Doherty et al. \[[@CR24]\], 199613430K/L71 (41--88)5610Duncan et al. \[[@CR25]\], 201141436K/L64.8 ± 8.15110Felson et al. \[[@CR31]\], 199586997.2\*K/L70.8 ± 5.06410Felson et al. \[[@CR30]\], 2007715 + 48830 + 120NR^§^, ACR criteria53 + 6653 + 4010Fraenkel et al. \[[@CR32]\], 199842348K/LNR6710Hart et al. \[[@CR37]\], 200283048Osteophytes, JSW54.1 ± 5.910010Kopec et al. \[[@CR43]\], 201225972K/LNR6510Lane et al. \[[@CR45]\], 199855108Osteophytes, JSW663310Larsson et al. \[[@CR46]\], 20127490OARSI50 (32--73)1810Mazzuca et al. \[[@CR51]\], 200631930K/L60.0 ± 9.68410McAlindon et al. \[[@CR54]\], 1996640120K/L70.36410Miyazaki et al. \[[@CR55]\], 20128496K/L72.3 ± 3.19310Muraki et al. \[[@CR57]\], 2012131340K/L68.7 ± 11.37510Nelsonet al. \[[@CR58]\], 201032960K/L61.9 ± 9.76110Pavelka et al. \[[@CR63]\], 200013960K/L59.1 ± 8.07610Reijman et al. \[[@CR66]\], 200753272K/L68.6 ± 7.06810Schouten et al. \[[@CR70]\], 1992239146.4\*K/L57.2 ± 6.15910Sharma et al. \[[@CR77]\], 200317118K/L64.0 ± 11.17410Spector et al. \[[@CR80]\], 199263132K/L60 and 617210Spector et al. \[[@CR82]\], 199784548K/LNR10010Sugiyama et al. \[[@CR83]\], 200311048JSW50.2 ± 6.010010Wilder et al. \[[@CR88]\], 200921767.2\*K/L65.9 ± 9.66110Yoshimura et al. \[[@CR91]\], 2012129636K/L636610Zhai et al. \[[@CR93]\], 200761884NR56-NR10Attur et al. \[[@CR2]\], 20119824K/L60.7569Bergink et al. \[[@CR7]\], 2009124872K/L66.2 ± 6.7589Bruyere et al. \[[@CR14]\], 200315736ACR criteria66.0 ± 7.3769Bruyere et al. \[[@CR15]\], 200315736ACR criteria66.0 ± 7.3769Felson et al. \[[@CR27]\], 200527030K/L66.6 ± 9.2409Golightly et al. \[[@CR35]\], 2010158372K/L60.9 ± 10.0649Harvey et al. \[[@CR38]\], 2010296430K/L62 ± 8589Haugen et al. \[[@CR39]\], 201226712OARSI61.0 ± 9.5559Kraus et al. \[[@CR44]\], 200913836K/LNR749Le Graverand et al. \[[@CR48]\], 200914124K/L561009Mazzuca et al. \[[@CR52]\], 20047330K/L55.2 ± 5.81009Nishimura et al. \[[@CR60]\], 20109248K/L71 ± 4.7619Peregoy and Wilder \[[@CR64]\], 201115772K/L66.5 ± 8.7569Reijman et al. \[[@CR65]\], 200423772K/L69.1 ± 6.9719Schouten et al. \[[@CR71]\], 1993239146K/L57.4 ± 6.3599Wolfe and Lane \[[@CR89]\], 200258331 + 102ACR criteria63.4 ± 11.8779Yusuf et al. \[[@CR92]\], 201115572K/L59.6 ± 7.5859Fayfman et al. \[[@CR26]\], 2009490120K/L60.5628Felson et al. \[[@CR28]\], 200422730K/L66.4 ± 9.4418Hunter et al. \[[@CR40]\], 200759536Clinical symptoms73.6 ± 2.9608Valdes et al. \[[@CR85]\], 2004280120K/L56.91008Kerkhof et al. \[[@CR41]\], 201083572K/L67646Kerna et al. \[[@CR42]\], 200914136K/LNR706Pavelka et al. \[[@CR62]\], 20048924ACR criteria56.7 ± 7.2666OA = osteoarthritis; K/L = Kellgren-Lawrence score; OARSI = Osteoarthritis Research Society International atlas; ACR = American College of Rheumatology; JSW = joint space width, cOA = clinical OA; rOA = radiographic OA; NR = not reported; \*mean followup in months; ^§^criteria not reported for one of the cohorts.

Study Results {#Sec8}
-------------

Because of the large number of studied determinants (n = 59), we pragmatically grouped our findings into five different categories: systemic factors (Table [3](#Tab3){ref-type="table"}); disease characteristics (Table [4](#Tab4){ref-type="table"}); intrinsic factors (Table [5](#Tab5){ref-type="table"}); extrinsic factors (Table [6](#Tab6){ref-type="table"}); and markers (Table [7](#Tab7){ref-type="table"}). Some authors presented statistically significant associations to OA progression, but used p values or regression coefficients as measures of association \[[@CR3], [@CR5], [@CR12], [@CR14], [@CR20], [@CR21], [@CR23], [@CR31], [@CR37], [@CR41], [@CR42], [@CR44], [@CR45], [@CR47], [@CR48], [@CR52], [@CR62], [@CR63], [@CR72], [@CR74], [@CR77], [@CR80], [@CR82], [@CR85], [@CR87], [@CR93]\]. We chose to present only OR, RR, or HR as measures of associations; however, we have tabulated whether there was a significant association with OA progression in an article.Table 3Systemic factors discussed in the reviewed studiesDeterminantStudyInstrument of measurementDefinition of knee OA progressionOR/RR/HR (95% CI)Association with OA progression\*Age\
(n = 3690)Bagge et al. \[[@CR3]\], 1992DichotomousIncrease K/L ≥ 1 (baseline K/L not provided)Not providedoBenichou et al. \[[@CR5]\], 2010\< 60 versus ≥ 60 yearsChange in JSW (mean difference)Not providedoDieppe et al. \[[@CR23]\], 1993JSN ≥ 2 mmNot providedoFelson et al. \[[@CR31]\], 1995Increase K/L ≥ 1 (baseline K/L ≥ 2)Not providedoMazzuca et al. \[[@CR51]\], 2006Continuous (years)Change in JSW (mean difference)OR 1.13 (0.87--1.48)oMiyazaki et al. \[[@CR56]\], 2002Continuous (years)JSN \> 1 grade on a 4-grade scaleOR 1.22 (1.05--1.41)+Muraki et al. \[[@CR57]\], 2012Per 5-year increaseIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 1.17 (1.05--1.30)+Nishimura et al. \[[@CR60]\], 2010Continuous (years)Increase K/L ≥ 1 (baseline K/L ≥ 2)OR 0.93 (0.83--1.06)oSchouten et al. \[[@CR70]\], 1992Fourth quartile versus firstChange in JSW ≥ 1 on a 9-point scaleOR 3.84 (1.10--13.4)+Wolfe and Lane \[[@CR89]\], 2002Continuous (years)JSN score = 3 on a 4-point scaleHR 1.00 (0.98--1.02)oFemale sex\
(n = 2235)Benichou et al. \[[@CR5]\], 2010Change in JSW (mean difference)Not providedoDieppe et al. \[[@CR23]\], 1993JSN ≥ 2 mmNot providedoFelson et al. \[[@CR31]\], 1995Increase K/L ≥ 1 (baseline K/L ≥ 2)RR 1.43 (0.80--2.58)oLedingham et al. \[[@CR47]\], 1995Increase K/L or JSW (cutoff not provided) Change in cyst size/numberNot provided\
OR 2.17 (1.13--4.15)o\
+Miyazaki et al. \[[@CR56]\], 2002JSN \> 1 grade on a 4-grade scaleOR 2.14 (0.34--13.5)oNishimura et al. \[[@CR60]\], 2010Increase K/L ≥ 1 (baseline K/L ≥ 2)OR 1.32 (0.22--7.75)oSchouten et al. \[[@CR70]\], 1992Change in JSW ≥ 1 on a 9-point scaleOR 0.50 (0.22--1.11)oSpector et al. \[[@CR80]\], 1992Change JSN ≥ 1 (4-grade scale), or ≥ 10% JSW reductionNot providedoWolfe and Lane \[[@CR89]\], 2002JSN score = 3 on a 4-point scaleHR 0.73 (0.44--1.19)oEthnicity\
(n = 1091)Kopec et al. \[[@CR43]\], 2012Black versus whiteIncrease K/L ≥ 1 (baseline K/L ≥ 2)HR 1.67 (1.05--2.67)+Low bone density\
(n = 3057)Hart et al. \[[@CR37]\], 2002Low versus highChange JSN ≥ 1 grade on a 4-grade scaleNot providedoNevitt et al. \[[@CR59]\], 2010High versus lowChange JSN ≥ 0.5 grade or osteophytes ≥ 1OR 1.3 (0.7--2.0)oZhang et al. \[[@CR94]\], 2000Fourth quartile (high) versus firstIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.1 (0.03--0.3)−Osteoporosis\
(n = 92)Nishimura et al. \[[@CR60]\], 2010Present versus absentIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 1.67 (0.44--6.28)oIGF-1\
(n = 662)Fraenkel et al. \[[@CR32]\], 1998Third tertile versus first in womenIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.9 (0.5--1.6)oThird tertile versus first in menIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.9 (0.3--3.0)oSchouten et al. \[[@CR71]\], 1993Third tertile versus firstChange ≥ 2 on a 5-point scale for radiographic OAOR 2.58 (1.01--6.60)+Metabolic syndrome (OW, HT, DL, IGT)\
(n = 1296)Yoshimura et al. \[[@CR91]\], 2012≥ 3 components versus noneIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 2.80 (1.68--4.68)+Two components versus noneOR 2.29 (1.49--3.54)+One component versus noneOR 1.38 (0.91--2.08)oEstrogen use\
(n = 551)Zhang et al. \[[@CR96]\], 1998Past use versus never usedIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.9 (0.6--1.4)oCurrent use versus never usedIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.4 (0.1--1.5)oUric acid concentration\
(n = 239)Schouten et al. \[[@CR70]\], 1992High tertile versus lowChange in JSW ≥ 1 on a 9-point scaleOR 1.36 (0.46--4.02)oMiddle versus lowChange in JSW ≥ 1 on a 9-point scaleOR 1.05 (0.36--3.00)oPlasma homocysteine\
(n = 490)Fayfman et al. \[[@CR26]\], 2009Third tertile versus first in men\
Third tertile versus first in womenIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.6 (0.1--1.1)\
OR 1.7 (0.8--3.8)o\
oGenetic components\
(n = 618)Zhai et al. \[[@CR93]\], 2007Hereditability in MZChange ≥ 1 in JSN or osteophyte scoreNot providedoHereditability in DZNot provided+SNP\
(n = 421)Kerna et al. \[[@CR42]\], 2009rs3740199 in womenIncrease JSN ≥ 1 or osteophyte gradeOR 2.66 (1.19--5.98)+rs1871054Increase JSN ≥ 1 or osteophyte gradeNot providedoValdes et al. \[[@CR85]\], 2004ADAM12_48Increase K/L ≥ 1 (baseline K/L not provided)Not providedoCILP_395Not provided+TNA_106Not providedoDepression/anxiety\
(n = 583)Wolfe and Lane \[[@CR89]\], 2002Depression, yes versus noJSN score = 3HR 1.09 (0.93--1.28)oAnxiety, yes versus noHR 0.95 (0.84--1.08)o\* Statistically significant association of the determinant with OA progression: + = positive association, − = negative association, o = no association (adjusted for age and sex if applicable); OA = osteoarthritis; K/L = Kellgren-Lawrence score; JSW = joint space width; JSN = joint space narrowing; IGF-1 = insulin-like growth factor 1; OW = overweight; HT = hypertension; DL = dyslipidemia; IGT = impaired glucose tolerance; MZ = monozygotic; DZ = dizygotic; SNP = single nucleotide polymorphisms; ADAM = A disintegrin and matrix metalloproteinase domain 12; CILP = cartilage intermediate-layer protein, nucleotide pyrophosphohydrolase; TNA = tetranectin (plasminogen-binding protein); OR = odds ratio; RR = relative risk; HR = hazard ratio; n = combined sample size.Table 4Disease characteristics discussed in the reviewed studiesDeterminantStudyInstrument of measurementDefinition of knee OA progressionOR/RR/HR (95% CI)Association with OA progression\*Knee pain\
(n = 2444)Cooper et al. \[[@CR18]\], 2000Present versus absentIncrease K/L ≥ 1 (baseline K/L ≥ 1)OR 0.8 (0.4--1.7)oIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 2.4 (0.7--8.0)oDieppe et al. \[[@CR23]\], 1993Present versus absentJSN ≥ 2 mmNot providedoMiyazaki et al. \[[@CR56]\], 2002Present versus absentChange JSN ≥ 1 grade on a 4-grade scaleOR 0.93 (0.78--1.11)oMuraki et al. \[[@CR57]\], 2012Present versus absentIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 2.63 (1.81--3.81+Spector et al. \[[@CR80]\], 1992Present versus absentChange JSN ≥ 1 grade on a 4-grade scale, or ≥ 10% JSNNot providedoWolfe and Lane \[[@CR89]\], 2002Present versus absentJSN score = 3 on a 4-point scaleHR 1.55 (1.07--2.24)+Severity Radiographic\
(n = 1874)Bruyere et al. \[[@CR15]\], 2003Severity high versus lowJSN ≥ 0.5 mmRR 2.39 (0.99--5.79)oDuncan et al. \[[@CR25]\], 2011Mild PFJOA versus none^†^Increase K/L ≥ 1 (baseline K/L ≥ 2) for TFJOAOR 4.5 (1.8--11.2)+Mild TFJOA versus none^†^Increase K/L ≥ 1 (baseline K/L ≥ 2) for PFJOAOR 1.7 (0.3--9.0)oLedingham et al. \[[@CR47]\], 1995Change ≥ 1 rOA feature versus no changeChange in attrition (cutoff not provided)\
Increase K/L or JSW (cutoff not provided)OR 1.72 (1.36--2.19)\
Not provided+\
oMazzuca et al. \[[@CR51]\], 2006JSW high versus low^†^Change in JSW (mean difference)OR 0.67 (0.49--0.91)+Patellofemoral OAChange in JSW (mean difference)OR 3.01 (1.63--5.57)+Miyazaki et al. \[[@CR56]\], 2002JSW, \> 3 versus \< 3 mmChange JSN ≥ 1 grade on a 4-grade scaleOR 0.74 (0.25--2.19)oPavelka et al. \[[@CR63]\], 2000JSW (continuous)Increase K/L ≥ 1 (baseline K/L not provided)Not providedoWolfe and Lane \[[@CR89]\], 2002Initial JSN, high versus lowJSN score = 3 on a 4-point scaleHR 2.62 (2.03--3.40)+Clinical\
(n = 1317)Dieppe et al. \[[@CR21]\], 1997Steinbrocker gradeJSN ≥ 2 mm, sclerosis, osteophytesNot providedoMazzuca et al. \[[@CR51]\], 2006WOMAC-PF^†^Change in JSW (mean difference)OR 1.16 (0.92--1.47)oWolfe and Lane \[[@CR89]\], 2002Global severity (continuous)JSN score = 3 on a 4-point scaleHR 1.02 (1.01--1.03)+HAQ, high versus lowJSN score = 3 on a 4-point scaleHR 1.34 (0.93--1.93)oHeberden nodes\
(n = 685)Cooper et al. \[[@CR18]\], 2000Increase K/L ≥ 1 (baseline K/L ≥ 1)OR 0.7 (0.4--1.6)oIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 2.0 (0.7--5.7)oNishimura et al. \[[@CR60]\], 2010Increase K/L ≥ 1 (baseline K/L ≥ 2)OR 2.01 (0.60--6.76)oSchouten et al. \[[@CR70]\], 1992Change in JSW ≥ 1 on a 9-point scaleOR 5.97 (1.54--23.1)+Osteoarthritis\
(n = 694)Haugen et al. \[[@CR39]\], 2012Score hand JSNIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 1.00 (0.93--1.08)oScore hand osteophytesOR 0.96 (0.87--1.06)oLedingham et al. \[[@CR47]\], 1995Multiple joints versus local joint OAIncrease K/L (cutoff not provided)OR 2.39 (1.16--4.93)+Change in attritionOR 2.42 (1.02--5.77)+Change in JSW or rOA (cutoff not provided)Not providedoSchouten et al. \[[@CR70]\], 1992Generalized OAChange in JSW ≥ 1 on a 9-point scaleOR 3.28 (1.30--8.27)+Localized OAChange in JSW ≥ 1 on a 9-point scaleOR 1.17 (0.51--2.72)oHand grip strength (muscle strength)\
(n = 1313)Muraki et al. \[[@CR57]\], 2012Per 1-kg strength increaseIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.99 (0.96--1.01)oDuration of symptoms\
(n = 643)Dieppe et al. \[[@CR23]\], 1993Continuous (years)JSN ≥ 2 mmNot providedoWolfe and Lane \[[@CR89]\], 2002Continuous (years)JSN score = 3 on a 4-point scaleHR 1.03 (1.00--1.05)+\* Statistically significant association of the determinant with OA progression: + = positive association, − = negative association, o = no association (adjusted for age and sex if applicable); ^†^at baseline; OA = osteoarthritis; K/L = Kellgren-Lawrence score; JSN = joint space narrowing; TFJOA = tibiofemoral joint OA; PFJOA = patellofemoral joint OA; JSW = joint space width; WOMAC-PF = physical function scale of the WOMAC; HAQ = Health Assessment Questionnaire; OR = odds ratio; RR = relative risk; HR = hazard ratio; n = combined sample size; rOA = radiographic OA.Table 5Intrinsic factors discussed in the reviewed studiesDeterminantStudyAnalysis of determinantDefinition of knee OA progressionOR/RR/HR (95% CI)Association with OA progression\*Alignment\
(n = 2642)Brouwer et al. \[[@CR13]\], 2007Varus versus neutralIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 2.90 (1.07--7.88)+Valgus versus neutralIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 1.39 (0.48--4.05)oCerejo et al. \[[@CR16]\], 2002Varus versus nonvarus (K/L 0--1)Change JSN \> 1 grade on a 4-grade scaleOR 2.50 (0.67--9.39)+Varus versus nonvarus (K/L 2)OR 4.12 (1.92--8.82)+Varus versus nonvarus (K/L 3)OR 11.0 (3.10--37.8)+Valgus versus nonvalgus (K/L 2)OR 2.46 (0.95--6.34)oValgus versus nonvalgus (K/L 3)OR 10.4 (2.76--39.5)+Hunter et al. \[[@CR40]\], 2007Patellar tilt, fourth versus first quartileMedial patellofemoral change JSN ≥ 1 grade on a 4-grade scaleOR 0.19 (0.09--0.43)−Sulcus angle, fourth versus first quartOR 1.49 (0.60--3.73)oBisect offset, fourth versus first quartOR 2.23 (1.10--4.50)+Patellar tilt, fourth versus first quartileLateral patellofemoral change JSN ≥ 1 grade on a 4-grade scaleOR 1.13 (0.57--2.24)oSulcus angle, fourth versus first quartOR 2.09 (0.99--4.41)oBisect offset, fourth versus first quartileOR 0.35 (0.15--0.83)−Miyazaki et al. \[[@CR56]\], 2002Varus versus nonvarusChange JSN ≥ 1 grade on a 4-grade scaleOR 0.90 (0.66--1.23)oSchouten et al. \[[@CR70]\], 1992Malaligned, present versus absentChange JSN ≥ 1 grade on a 4-grade scaleOR 5.13 (1.14--23.1)+Sharma et al. \[[@CR79]\], 2001Varus versus nonvarusChange JSN ≥ 1 grade on a 4-grade scaleOR 4.09 (2.20--7.62)+Varus versus mild valgusOR 2.98 (1.51--5.89)+Valgus versus nonvalgusOR 4.89 (2.13--11.2)+Valgus versus mild varusOR 3.42 (1.31--8.96)+Sharma et al. \[[@CR78]\], 2010Valgus versus neutralChange medial JSN ≥ 1 grade on a 4-grade scaleOR 0.34 (0.21--0.55)−Varus versus neutralOR 3.59 (2.62--4.92)+Valgus versus neutralChange lateral JSN ≥ 1 grade on a 4-grade scaleOR 4.85 (3.17--7.42)+Varus versus neutralOR 0.12 (0.07--0.21)−Yusuf et al. \[[@CR92]\], 2011Varus (\< 182°) versus nonvarusChange JSN ≥ 1 grade on a 6-grade scaleRR 2.3 (1.4--3.1)+Valgus (\> 184°) versus nonvalgusRR 1.7 (0.97--2.6)oMalaligned, BMI \> 25 kg/m^2^RR 4.1 (1.8--6.1)+Adduction moment\
(n = 74)Miyazaki et al. \[[@CR56]\], 2002≥ 5 versus \< 5 (% weight x height)Change JSN ≥ 1 grade on a 4-grade scaleOR 6.46 (2.40--17.5)+Knee injury\
(n = 207)Cooper et al. \[[@CR18]\], 2000Yes versus noIncrease K/L ≥ 1 (baseline K/L ≥ 1)OR 1.2 (0.5--3.0)oIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 1.1 (0.3--4.4)oSchouten et al. \[[@CR70]\], 1992Knee injury: yes versus noChange JSN ≥ 1 grade on a 4-grade scaleOR 2.62 (0.93--7.36)oSport injury: yes versus noChange JSN ≥ 1 grade on a 4-grade scaleOR 0.62 (0.17--2.19)oBone marrow lesions/edema\
(n = 186)Madan-Sharma et al. \[[@CR50]\], 2008Present versus absentJSN \> 1 grade on a 4-grade scaleRR 0.9 (0.18--3.0)oSubchondral bone cysts (MRI)\
(n = 186)Madan-Sharma et al. \[[@CR50]\], 2008Present versus absentJSN \> 1 grade on a 4-grade scaleRR 1.6 (0.5--4.0)oCartilage loss (MRI)\
(n = 186)Madan-Sharma et al. \[[@CR50]\], 2008Present versus absentJSN \> 1 grade on a 4-grade scaleRR 3.0 (0.5--9.6)oJoint effusion\
(n = 186)Madan-Sharma \[[@CR50]\], 2008Present on MRIJSN \> 1 grade on a 4-grade scaleRR 0.6 (0.6--1.8)oMeniscal damage\
(n = 186)Madan-Sharma et al. \[[@CR50]\], 2008Present versus absent on MRIJSN \> 1 grade on a 4-grade scaleRR 8.91 (1.1--22.8)+Meniscectomy\
(n = 239)Schouten et al. \[[@CR70]\], 1992Yes versus noChange JSN ≥ 1 grade on a 4-grade scaleOR 2.28 (0.57--9.03)oChondrocalcinosis\
(n = 239)Schouten et al. \[[@CR70]\], 1992Yes versus noChange JSN ≥ 1 grade on a 4-grade scaleOR 2.01 (0.55--7.42)oOsteophytes tibiofemoral\
(n = 337)Benichou et al. \[[@CR5]\], 2010Definite versus notChange in JSW (mean difference)Not providedoFelson et al. \[[@CR27]\], 2005Ipsilateral score\
Contralateral scoreChange JSN ≥ 1 grade on a 4-grade scaleOR 1.9 (1.5--2.5)+OR 0.6 (0.5--0.8)−Knee ROM\
(n = 92)Nishimura et al. \[[@CR60]\], 2010Mean ROMIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.94 (0.89--0.99)−\* Statistically significant association of the determinant with OA progression: + = positive association, − = negative association, o = no association (adjusted for age and sex if applicable); OA = osteoarthritis; K/L = Kellgren-Lawrence score; JSN = joint space narrowing; JSW = joint space width; OR = odds ratio; RR = relative risk; HR = hazard ratio; n = combined sample size.Table 6Extrinsic factors discussed in the reviewed studiesDeterminantStudyAnalysis of determinantDefinition of knee OA progressionOR/RR/HR (95% CI)Association with OA progression\*BMI\
(n = 6791)Benichou et al. \[[@CR5]\], 2010\< 30 versus ≥ 30 kg/m^2^Change in JSW (mean difference)Not provided+Cooper et al. \[[@CR18]\], 2000Highest tertile versus lowestIncrease K/L ≥ 1 (baseline K/L ≥ 1)OR 2.6 (1.0--6.8)+Increase K/L ≥ 1 (baseline K/L ≥ 2)OR 1.3 (0.3--5.0)oDieppe et al. \[[@CR23]\], 1993ContinuousJSN ≥ 2 mm or knee surgeryNot providedoFelson et al. \[[@CR28]\], 2004Per 2-unit increase (§)Change JSN ≥ 1 grade on a 4-grade scaleOR 0.98 (0.8--1.4)oAs §, with 3°--6° malalignmentOR 1.23 (1.0--1.4)+As §, with ≥ 7° malalignmentOR 0.93 (0.7--1.2)oLedingham et al. \[[@CR47]\], 1995ContinuousChange in JSW (cutoff not provided)OR 1.07(1.02--1.14)+Change in osteophytes (cutoff not provided)OR 1.06 (1.00--1.12)+Change in K/L (cutoff not provided)Not providedoLeGraverand et al. \[[@CR48]\], 2009\< 30 versus ≥ 30 kg/m^2^Change in JSW (mean difference)Not providedoMiyazaki et al. \[[@CR56]\], 2002ContinuousJSN ≥ 1 grade on a 4-grade scaleOR 1.21 (0.91--1.61)oMuraki et al. \[[@CR57]\], 2012Per 5-unit increaseIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 1.43 (1.16--1.77)+Nishimura et al. \[[@CR60]\], 2010ContinuousIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.93 (0.78--1.11)oNiu et al. \[[@CR61]\], 2009\< 25 versus ≥ 30 kg/m^2^Increase JSN ≥ 0.5 gradeRR 1.1 (0.9--1.4)oReijman et al. \[[@CR66]\], 2007≤ 25 versus \> 27.5 kg/m^2^Increase JSN ≥ 1 mmOR 1.4 (0.8--2.6)oIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 2.1 (1.2--3.7)+Schouten et al. \[[@CR70]\], 1992Second quartile versus firstChange in JSW ≥ 1 on a 9-point scaleOR 1.77 (0.48--6.50)oThird quartile versus firstOR 5.28 (1.54--18.1)+Fourth quartile versus firstOR 11.1 (3.28--37.3)+Spector et al. \[[@CR81]\], 1994Third tertile versus firstIncrease K/L or JSN (cutoff not provided)RR 4.69 (0.63--34.8)oWolfe and Lane \[[@CR89]\], 2002ContinuousJSN score = 3HR 1.03 (1.00--1.06)+Yusuf et al. \[[@CR92]\], 2011BMI 25--30 versus \< 25Change JSN ≥ 1 grade on a 6-grade scaleRR 2.4 (1.3--3.6)+BMI \>30 versus \< 25Change JSN ≥ 1 grade on a 6-grade scaleRR 2.9 (1.7--4.1)+Quadriceps strength\
(n = 253)Brandt et al. \[[@CR12]\], 1999Progressive versus nonprogressive group^†^Increase K/L ≥ 1 (baseline K/L not provided)Not providedoSharma et al. \[[@CR77]\], 2003High versus low strength^†^Increase JSN ≥ 1Not providedoLeg length inequality\
(n = 4547)Golightly et al. \[[@CR35]\], 2010Leg length inequality versus no inequalityIncrease K/L ≥ 1 (baseline K/L ≥ 1)HR 1.22 (0.82--1.80)oIncrease K/L ≥ 1 (baseline K/L ≥ 2)HR 1.83 (1.10--3.05)+Harvey et al. \[[@CR38]\], 2010≥ 1 cm versus no inequality, shorter legJSN ≥ 1 grade or knee surgeryOR 1.3 (1.0--1.7)+≥ 2 cm versus no inequality, shorter legOR 1.4 (0.5--3.7)oAP knee laxity\
(n = 84)Miyazaki et al. \[[@CR55]\], 2012Before exerciseIncrease K/L ≥ 1 (baseline K/L ≥ 1) or radiographic cartilage loss \> 0.2 mm annuallyOR 1.29 (0.54--3.08)oEnhanced laxity resulting from exerciseOR 4.15 (1.12--15.4)+Running\
(n = 294)Lane et al. \[[@CR45]\], 1998Dichotomous^‡^Increase ≥ 1 on JSW and osteophyte scoreNot providedoSchouten et al. \[[@CR70]\], 1992Dichotomous^†^Change in JSW ≥ 1 on a 9-point scaleOR 0.53 (0.17--1.68)oRegular sports\
(n = 593)Cooper et al. \[[@CR18]\], 2000Dichotomous^†^Increase K/L ≥ 1 (baseline K/L ≥ 1)OR 0.7 (0.4--1.6)oIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.9 (0.3--2.5)oSchouten et al. \[[@CR70]\], 1992Physical activity^‡^Change in JSW ≥ 1 on a 9-point scaleOR 0.43 (0.11--1.76)oWalking^‡^OR 1.47 (0.36--6.03)oStanding (medium versus low)^‡^OR 3.80 (1.03--14.0)+Standing (high versus low)^‡^OR 2.09 (0.43--10.3)oNutritional variables\
(n = 3381)Bergink et al. \[[@CR7]\], 2009Vitamin D intake (low versus high)Increase K/L ≥ 1 (baseline K/L ≥ 2)OR 7.7 (1.3--43.5)−Serum vitamin D (low versus high)Increase K/L ≥ 1 (baseline K/L ≥ 2)OR 2.1 (0.6--7.4)oFelson et al. \[[@CR30]\], 2007Vitamin D serum levels \< 20 ng/mLChange JSN ≥ 1 grade on a 4-grade scale, FraminghamOR 0.83 (0.54--1.27)oVitamin D serum levels \< 20 ng/mLChange JSN ≥ 1 grade on a 4-grade scale, BOKS studyOR 0.63 (0.35--1.14)oMcAlindon et al. \[[@CR53]\], 1996Vitamin D intake (middle versus high)Increase JSN ≥ 1OR 2.99 (1.06--8.49)−Serum vitamin D (middle versus high)Increase JSN ≥ 1OR 2.83 (1.02--7.85)−McAlindon et al. \[[@CR54]\], 1996Vitamin C intake (middle versus low)Increase K/L ≥ 1OR 0.32 (0.14--0.77)−β-carotene intake (high versus low)OR 0.42 (0.19--0.94)−Vitamin E (high versus low)OR 0.68 (0.28--1.64)oPeregoy and Wilder \[[@CR64]\], 2011Vitamin C intakeIncrease K/L ≥ 1 (baseline K/L ≥ 2)RR 0.94 (0.79--1.12)oWilder et al. \[[@CR88]\], 2009Vitamin intake in generalIncrease K/L ≥ 1 (baseline K/L ≥ 2)RR 0.93 (0.87--0.99)−Smoking\
(n = 331)Nishimura et al. \[[@CR60]\], 2010Yes versus noIncrease K/L ≥ 1 (baseline K/L ≥ 2)OR 0.73 (0.09--6.15)oSchouten et al. \[[@CR70]\], 1992Past smoker versus neverChange in JSW ≥ 1 on a 9-point scaleOR 1.07 (0.38--3.04)oCurrent smoker versus neverChange in JSW ≥ 1 on a 9-point scaleOR 0.96 (0.34--2.75)o\* Statistically significant association of the determinant with OA progression: + = positive association, − = negative association, o = 1o association (adjusted for age and sex if applicable); ^†^assessed at baseline; ^‡^assessed at followup; OA = osteoarthritis; JSW = joint space width; K/L = Kellgren-Lawrence score; JSN = joint space narrowing; OR = odds ratio; RR = relative risk; HR = hazard ratio; n = combined sample size.Table 7Markers discussed in the reviewed studiesMarkerStudyInstrument of measurementDefinition of knee OA progressionOR/RR/HR (95% CI)Association with OA progression\*CRP (serum)\
(n = 1720)Kerkhof et al. \[[@CR41]\], 2010ContinuousIncrease K/L ≥ 1 (baseline K/L ≥ 2) or surgeryNot providedoSharif et al. \[[@CR76]\], 2000ContinuousJSN ≥ 2 mm or knee surgeryOR 1.12 (0.81--1.55)oSpector et al. \[[@CR82]\], 1997ContinuousIncrease K/L ≥ 1 (baseline K/L not provided)Not provided+IL-1β (serum)\
(n = 184)Attur et al. \[[@CR2]\], 2011Increased versus normalIncrease K/L ≥ 1 or \> 30% JSW reductionOR 3.2 (1.2--8.7)+Botha-Scheepers et al. \[[@CR11]\], 2008Fourth quartile versus firstChange JSN ≥ 1 grade on a 4-grade scaleRR 1.3 (0.5--2.0)oIL-10 (serum)\
(n = 86)Botha-Scheepers et al. \[[@CR11]\], 2008Fourth quartile versus firstChange JSN ≥ 1 grade on a 4-grade scaleRR 4.3 (1.7--6.2)+IL-1Ra (serum)\
(n = 86)Botha-Scheepers et al. \[[@CR11]\], 2008Fourth quartile versus firstChange JSN ≥ 1 grade on a 4-grade scaleRR 2.1 (0.7--3.9)oTNFα (serum)\
(n = 253)Attur et al. \[[@CR2]\], 2011Increased versus normalIncrease K/L ≥ 1 or \> 30% JSW reductionOR 8.9 (2.6--30.8)+Botha-Scheepers et al. \[[@CR11]\], 2008Fourth quartile versus firstChange JSN ≥ 1 grade on a 4-grade scaleRR 6.1 (1.4--9.8)+Denoble et al. \[[@CR20]\], 2011ContinuousChange in osteophyte scoreNot provided+TGF-β1 (serum)\
(n = 329)Nelson et al. \[[@CR58]\], 2010ContinuousIncrease K/L ≥ 1 (baseline K/L ≥ 1)HR 1.04 (0.41--2.65)oIncrease K/L ≥ 1 (baseline K/L ≥ 2)HR 1.10 (0.46--2.63)oHyaluronic acid (serum)\
(n = 361)Bruyere et al. \[[@CR14]\], 2003High level versus lowChange in mean JSW (cutoff not provided)Not provided+Pavelka et al. \[[@CR62]\], 2004High level versus lowChange in mean JSW (cutoff not provided)Not provided+Sharif et al. \[[@CR72]\], 1995High level versus lowJSN ≥ 2 mm or knee surgeryNot provided+Sharif et al. \[[@CR76]\], 2000High level versus lowJSN ≥ 2 mm or knee surgeryOR 2.32 (1.16--4.66)+Keratan sulfate (serum)\
(n = 232)Bruyere et al. \[[@CR14]\], 2003High level versus lowChange in mean JSW (cutoff not provided)Not provided+Sharif et al. \[[@CR72]\], 1995High level versus lowJSN ≥ 2 mm or knee surgeryNot providedoCOMP (serum)\
(n = 466)Bruyere et al. \[[@CR14]\], 2003High level versus lowChange in mean JSW (cutoff not provided)Not providedoPavelka et al. \[[@CR62]\], 2004High level versus lowChange in mean JSW (cutoff not provided)Not providedoSharif et al. \[[@CR75]\], 1995High level versus lowJSN ≥ 2 mm or knee surgeryNot provided+Sharif et al. \[[@CR74]\], 2004OA progression versus nonprogessionJSN ≥ 2 mm or knee surgeryNot provided+Vilim et al. \[[@CR87]\], 2002High level versus lowJSN \> 0.5 mmNot provided+Pentosidine (serum)\
(n = 89)Pavelka et al. \[[@CR62]\], 2004High level versus lowChange in mean JSW (cutoff not provided)Not provided+YKL-40 (serum)\
(n = 89)Pavelka et al. \[[@CR62]\], 2004High level versus lowChange in mean JSW (cutoff not provided)Not providedoMMP-9 (serum)\
(n = 89)Pavelka et al. \[[@CR62]\], 2004High level versus lowChange in mean JSW (cutoff not provided)Not providedoTIMP-9 (serum)\
(n = 89)Pavelka et al. \[[@CR62]\], 2004High level versus lowChange in mean JSW (cutoff not provided)Not providedoPIIANP (serum)\
(n = 115)Sharif et al. \[[@CR73]\], 2007Fourth quartile versus firstJSN ≥ 2 mm or knee surgeryRR 3.2 (1.1--9.0)+CTX-II (urine)\
(n = 490)Dam et al. \[[@CR19]\], 2009Third tertile versus firstIncrease K/L ≥ 1 (disregarding baseline K/L)OR 2.3oThird tertile versus firstJSN \> mean JSN of non-OA control group (K/L ≤ 1)OR 1.8oReijman et al. \[[@CR65]\], 2004Fourth quartile versus firstJSN ≥ 2 mmOR 6.0 (1.2--30.8)+Fourth quartile versus firstJSN ≥ 1.5 mmOR 1.8 (0.8--4.1)oFourth quartile versus firstJSN ≥ 1 mmOR 1.1 (0.7--1.7)oSharif et al. \[[@CR73]\], 2007\> median versus ≤ medianJSN ≥ 2 mm or knee surgeryRR 3.4 (1.2--9.4)+ARGS (synovial)\
(n = 74)Larsson et al. \[[@CR46]\], 2012Baseline level ARGS \> followup level ARGS≥ 1-unit increase OARSI scoreOR 6.77 (1.38--33.2)+IL-18 (synovial)\
(n = 69)Denoble et al. \[[@CR20]\], 2011ContinuousChange in osteophyte scoreNot provided+FSA (radiographic)\
(n = 138)Kraus et al. \[[@CR44]\], 2009FD progression versus nonprogressionMedial JSN ≥ 1 or osteophyte formationNot provided+Bone scintigraphy\
(n = 73)Mazzuca et al. \[[@CR52]\], 2004^99m^Tc-MDP uptakeChange in JSW (mean difference)Not providedo\* Statistically significant association of the determinant with OA progression: + = positive association, − = negative association, o = no association (adjusted for age and sex if applicable); OA = osteoarthritis; K/L = Kellgren-Lawrence score; JSN = joint space narrowing; CRP = C-reactive protein; IL = interleukin; TNF = tumor necrosis factor; YKL-40 = chitinase-3-like protein 1; JSW = joint space width; TGF = transforming growth factor; C2C = collagen type II cleavage; COMP = cartilage oligomeric matrix protein; MMP = matrix metalloproteinase; TIMP = tissue inhibitors of metalloproteinase; PIIANP = N-propeptide of type IIA collagen; CTX-II = crosslinked C-telopeptide; ARGS = aggrecan neoepitope amino acid sequence; FSA = fractal signature analysis; FD = fractal dimension (horizontal and vertical); OR = odds ratio; RR = relative risk; HR = hazard ratio; n = combined sample size.

Sensitivity Analysis {#Sec9}
--------------------

For factors in which we were forced to use a best-evidence synthesis, we conducted a sensitivity analysis to check whether differences in sample size could have altered our conclusions. Additionally we checked whether large variances in followup could have led to different conclusions.

Results {#Sec10}
=======

Summaries of the results for systemic factors, disease characteristics, intrinsic factors, extrinsic factors, and markers are available (Appendix 2. Supplemental material is available with the online version of CORR^®^.).

Pooled Results {#Sec11}
--------------

The presence of knee pain at baseline and Heberden nodes were associated with the progression of knee OA. The pooled ORs based on pools of studies with consistency among the definitions for OA inclusion, OA progression, and the determinant under study, were 2.38 for knee pain at baseline (95% CI,1.74--3.27; I^2^ = 52%) (Fig. [1](#Fig1){ref-type="fig"}) and 2.66 for the presence of Heberden nodes (95% CI, 1.46--8.84); I^2^ = 0%) (Fig. [2](#Fig2){ref-type="fig"}). Because of the large number of determinants with only a restricted number of studies per determinant and owing to lack of consistency between the reviewed studies regarding inclusion criteria, outcome measures, and measures of association, statistical pooling was not possible for the majority of the determinants.Fig. 1A forest plot for the pooled odds ratio (OR) shows the association between the presence of knee pain at baseline and radiographic progression of knee osteoarthritis (OA). The OR can deviate from the OR in Table [4](#Tab4){ref-type="table"} because pooled ORs were obtained through crude ORs, as opposed to the adjusted OR in Table [4](#Tab4){ref-type="table"}. The results from Dieppe and Wolfe for pooling were not available and were not included in this analysis. The results from the chi-square and I^2^ tests indicate homogeneity between the studies. M--H = Mantel Haenszel test; Fixed = fixed effects model; df = degrees of freedom.Fig. 2A forest plot for the pooled odds ratio (OR) shows the association between the presence of Heberden nodes at baseline and radiographic progression of knee osteoarthritis (OA). The OR can deviate from that in Table [4](#Tab4){ref-type="table"} because pooled ORs were obtained through crude ORs, as opposed to the adjusted OR in Table [4](#Tab4){ref-type="table"}. The results from the chi-square and I^2^ tests indicate homogeneity between the studies. M--H = Mantel Haenszel test; Fixed = fixed effects model; df = degrees of freedom.

Best-evidence Synthesis {#Sec12}
-----------------------

For the remaining determinants, we applied a best-evidence synthesis, which showed that based on consistent findings in multiple high-quality studies, there seems to be strong evidence that varus alignment, serum TNFα level, and serum hyaluronic acid level are associated with radiographic progression of knee OA. There also is strong evidence that sex (female), former knee injury, quadriceps strength, smoking, running, and regular performance of sports are not associated with progression of knee OA.

There was moderate evidence showing that a higher dietary intake of vitamin D is inversely associated with progression of knee OA. Thus far, there is limited evidence that ethnicity, metabolic syndrome, genetic components adduction moment, meniscal damage, knee ROM, general vitamin and β-carotene intake, serum levels IL-10 and N-propeptide of type II collagen, synovial levels aggrecan neoepitope amino acid sequence and IL-18, and fractal dimension progression on radiographic fractal signature analysis are associated with progression of knee OA. There also is limited evidence that knee OA progression is not associated with osteoporosis; past or present estrogen use; uric acid concentrations; depression or anxiety; hand grip (muscle) strength; bone marrow lesions or edema; meniscectomy; chondrocalcinosis; MRI-detected subchondral bone cysts, cartilage loss, or joint effusion; AP knee laxity; vitamin E intake; serum levels IL-1Ra and transforming growth factor-β1; and ^99m^Tc-MDP uptake on bone scintigraphy.

Conflicting evidence was found for the associations between knee OA progression and age; low bone density; serum insulin growth factor-1 level; baseline radiographic or clinical OA severity; generalized osteoarthritis; duration of symptoms; valgus alignment or malalignment in general; past knee injury; the presence of tibiofemoral osteophytes; BMI; leg length inequality; serum vitamin D level; dietary intake of vitamin C; serum C-reactive protein, IL-1β, keratan sulfate, and serum cartilage oligometric matrix protein levels, and urinary crosslinked C-telopeptide level. Inconclusive evidence was found for the determined associations between knee OA progression and the single nucleotide polymorphisms CILP_395 (cartilage intermediate-layer proteins) and rs3740199, patellofemoral alignment, and serum pentosidine levels. There also was inconclusive evidence for no associations found between knee OA progression and the single nucleotide polymorphisms rs1871054, ADAM12_48 (A disintegrin and matrix metalloproteinase domain 12), and TNA_106 (tetranectin plasminogen-binding protein), and serum levels of YKL-40 (chitinase-3-like protein 1), MMP-9 (matrix metalloproteinase-9); and TIMP-9 (tissue inhibitors of metalloproteinase).

Sensitivity Analysis {#Sec13}
--------------------

In this analysis, we tested whether conclusions from relatively small studies (less than 200) incorrectly influenced conclusions drawn from larger studies with more statistical power studying the same determinant, or that results from studies with a relatively short followup (cutoff 24 months) altered conclusions from studies with a longer followup. Our sensitivity analysis found that our conclusions did not change across the range of clinically plausible differences in followup duration or sample size regarding the strong, moderate, or conflicting evidence we found for the various presented determinants.

Discussion {#Sec14}
==========

We performed an updated systematic review of available evidence regarding prognostic factors for radiographic knee OA progression. We found that there is strong evidence that baseline knee pain and Heberden nodes, varus alignment, and high baseline serum levels of hyaluronic acid and TNFα are predictive for knee OA progression. There also seems to be strong evidence that sex (female), former knee injury, quadriceps strength, smoking, running, and regular performance of sports are not predictive for progression of knee OA. For all other studied factors in our review, the evidence is limited, conflicting, or inconclusive. In the best-evidence synthesis, we considered only significant associations as associated prognostic factors. However, several of the included articles had small sample sizes, which consequently can lead to lower statistical power and more often to failure to detect differences that might be present.

A possible limitation to our inclusion criteria was addressed by Zhang et al. \[[@CR97]\]. They reported that, unlike randomized trials, observational studies of patients with preexisting disease are subject to various biases that may account for discrepancies found between risk factors for disease incidence and progression. They hypothesized that risk factors actually might exist for progressive knee OA but that flaws in study design and the measure of disease progression may prevent us from detecting risk factors \[[@CR97]\]. Having cited their article, it seems reasonable that there is the possibility that we have not determined all risk factors for progression of knee OA, because some factors might not have achieved significance in multivariable analyses in a study and thus were not included in our evidence synthesis. Nonetheless, we believe we have summarized all presently known risk factors of which a possible association with knee OA progression has been studied.

We acknowledge that when applying a best-evidence synthesis, one might unjustly conclude that there may be conflicting or strong evidence for or against an association of the determinant under study with knee OA. We would have preferred to pool the data of all included studies. However, because of large variation in criteria used in the articles for defining disease, or disease progression, pooling of the data generally was not possible. We encountered six different criteria that were used for the inclusion of OA (Table [2](#Tab2){ref-type="table"}). Another approximately 13 different definitions were applied for OA progression (Tables [3](#Tab3){ref-type="table"}--[7](#Tab7){ref-type="table"}). Furthermore, there were differences in how the determinants under study were measured, (continuous, dichotomous, or categorical), and varying cutoff points were used. As previously described, we pooled the results for "knee pain" and "Heberden nodes" for which both results showed associations with the progression of knee OA. This is different from the conclusions we would have drawn from a best-evidence synthesis, which would show conflicting evidence for both determinants. In our opinion, it is likely that more of the conflicting associations we presented are attributable to the differences in definitions of knee OA or knee OA progression. For example, the conflicting evidence for BMI probably would be altered if statistical pooling was feasible; given that all 11 significant risk estimates (OR/RR/HR) regarding BMI were positive associations and that six of the 12 nonsignificant associations also were positive associations, it seems likely that if pooled, the combined overall association between BMI and knee OA would be a positive, significant one. In addition, the conflicting evidence for age, seven of the 10 presented analyses (70%) showed no significant association, falling just short for the criteria for ascertaining strong evidence (\> 75%) for no association between age and OA progression.

In the original review by Belo et al. \[[@CR4]\] and in a review by van Dijk et al. \[[@CR86]\], the evidence for association between varus alignment and OA progression was limited. However, a couple studies have been performed since these reviews were published that have determined significant associations with varus alignment, which enabled us to conclude that there is strong evidence for this finding. The latter is in accordance with results published in later systematic reviews by Tanamas et al. \[[@CR84]\] and Chapple et al. \[[@CR17]\]. Except for the original review by Belo et al., there are to our knowledge no other reviews available that have determined the predictive value of serum hyaluronic acid levels and OA progression \[[@CR9]\]. In addition, to our knowledge, no reviews have been published assessing the predictive value of serum level TNFα for knee OA progression.

We found strong evidence that sex was not associated with knee OA progression, as did Belo et al. \[[@CR4]\]. This is in contrast to the earlier reviews published by van Dijk et al. \[[@CR86]\] and Chapple et al. \[[@CR17]\]. van Dijk et al. found limited evidence for the absence of an association with sex, but they included articles that used physical functioning as an outcome measure. Chapple et al. found conflicting evidence; however, their evidence was based on four analyses of three studies, which also are included in our review \[[@CR21], [@CR47], [@CR70]\]. Three of the four analyses were consistent (no association); one was conflicting (significant association) \[[@CR47]\]. Our evidence synthesis was based on 10 analyses, of which nine analyses were consistent (no association), consequently outweighing the one conflicting finding. van Dijk et al. and Chapple et al. reported limited evidence for the absence of an association between quadriceps strength and knee OA progression. This is consistent with our finding; however, our conclusion is based on more evidence. Consistent results also were found for regular performance of sports, in which van Dijk et al. reported limited and Chapple et al. reported strong evidence for absence of an association. However, in articles by Fransen and McConnell \[[@CR33]\] and Bennell and Hinman \[[@CR6]\] reviewing the effect of exercise therapy in patients with knee OA, the authors reported that exercise has a short-term benefit in patients with knee OA, although the magnitude of the reported benefit is small. This highlights the importance of the need to understand the working mechanism of exercise therapy.

A topic of considerable interest is the potential association between BMI and knee OA progression. Previous reviewers have established a positive association between BMI and incident knee OA \[[@CR10], [@CR95]\]. However, the evidence for an association between BMI and progression of knee OA remains conflicting in our review, which is consistent with the findings by Belo et al. \[[@CR4]\] and Chapple et al. \[[@CR17]\].

Noteworthy is the lack of overlap in evidence for prognostic factors for hip and knee OA progression. In two large reviews studying prognostic factors for hip OA, Lievense et al. \[[@CR49]\] provided strong evidence for an association between hip OA progression with type of hip migration and with atrophic bone response. They also presented strong evidence for the absence of an association with BMI. Wright et al. \[[@CR90]\] reported strong evidence for association of hip OA progression with age, joint space width at entry, femoral head migration, femoral osteophytes, bony sclerosis, baseline hip pain, and certain hip OA severity indexes. They also provided strong evidence for the absence of an association with acetabular osteophytes. The discrepancy between the findings for hip and knee OA is unclear but could be attributable to the difference in the number of studies available determining risk factors for progression of hip or knee OA \[[@CR9]\].

Future research on the true relationship between prognostic factors for radiographic progression of knee OA is needed, mainly on the factors where conflicting evidence was presented (eg, age, baseline OA severity, BMI). Furthermore, we presented limited, inconclusive, or conflicting evidence on many factors with potential associations with OA progression. It would be important to investigate determinants that can be influenced or modified to reduce the risk of OA progression, perhaps including metabolic syndrome, bone marrow lesions, or osteoporosis. Moreover, there would be obvious advantages to testing the effect of new or existing disease-modifying pharmacologic or surgical interventions in patients with an established increased risk of OA progression.

We found strong evidence that baseline knee pain and Heberden nodes, varus alignment, and high baseline serum levels of hyaluronic acid and TNFα are predictive for knee OA progression. Sex (female), former knee injury, quadriceps strength, smoking, running, and regular performance of sports are not predictive for progression of knee OA. Many studies have been performed and are being performed determining risk factors for knee OA progression, but the variability in how OA and OA progression are defined across the relevant studies remains an impediment to pooling the available evidence. We strongly recommend future researchers use uniform definitions of determinants, disease, and disease progression; it would enable more precise determination of possible risk factors for knee OA progression through meta-analyses. The majority of the included studies used the Kellgren-Lawrence classification as definition of disease and disease progression. This classification has been criticized because the criteria have been described and interpreted differently in various studies \[[@CR67]\]. However, the Kellgren-Lawrence criteria provide a reliable classification of knee OA and OA progression, given that the original description of the criteria are applied \[[@CR67], [@CR68]\]. We therefore recommend that future researchers use the Kellgren-Lawrence classification to define radiographic OA and OA progression. Furthermore, considering that some MRI scoring systems have been and currently are being developed to define knee OA progression \[[@CR36]\], it seems preferable that the same MRI scoring system would be used universally in future studies on prognostic factors for knee OA progression. We would like to call on expert committees, such as the Osteoarthritis Research Society International (OARSI) for OA Imaging to announce their recommendations on this important topic.
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